Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
To evaluate whether AMG 386 in combination with paclitaxel and carboplatin is safe and well
tolerated in the first-line treatment of high-risk stage I and stages II-IV epithelial
ovarian, primary peritoneal and fallopian tube cancers. The hypothesis is that AMG 386 in
combination with carboplatin and paclitaxel is safe and well tolerated.